trending Market Intelligence /marketintelligence/en/news-insights/trending/d9J6uYnQKRSHEDBXGZlqPQ2 content esgSubNav
In This List

Thermo Fisher, Juno Therapeutics ink CAR-T licensing, supply deal

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Thermo Fisher, Juno Therapeutics ink CAR-T licensing, supply deal

Thermo Fisher Scientific Inc. and Juno Therapeutics Inc. entered into a partnership for Juno to use Thermo Fisher's Cell Therapy Systems activation reagents in the manufacturing of its chimeric antigen receptor T cell, or CAR-T cell, therapies.

Under the seven-year nonexclusive licensing and supply agreement, Thermo Fisher granted Juno rights to use CTS Dynabeads CD3/CD28 magnetic beads as part of the clinical and commercial manufacturing processes for Juno's current and future CAR-T cell therapies, which work by manipulating a patient's own disease-fighting T-cells and then infusing them back into the body to fight blood cancers.

CTS Dynabeads activate and expand T-cells that have been genetically engineered to recognize and fight cancer cells in each individual patient.

The companies did not disclose the financial details of the transaction.